Lyell Immunopharma, Inc. (LYEL): Price and Financial Metrics


Lyell Immunopharma, Inc. (LYEL): $4.34

0.25 (+6.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LYEL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LYEL Stock Price Chart Interactive Chart >

Price chart for LYEL

LYEL Price/Volume Stats

Current price $4.34 52-week high $19.84
Prev. close $4.09 52-week low $3.57
Day low $4.06 Volume 634,000
Day high $4.38 Avg. volume 1,072,377
50-day MA $5.00 Dividend yield N/A
200-day MA $8.91 Market Cap 1.07B

Lyell Immunopharma, Inc. (LYEL) Company Bio


Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, as well as ovarian and other solid tumors; LYL845, an IV administered autologous TIL therapy for multiple solid tumors; and NY-ESO-1, a T cell product candidate for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.


LYEL Latest News Stream


Event/Time News Detail
Loading, please wait...

LYEL Latest Social Stream


Loading social stream, please wait...

View Full LYEL Social Stream

Latest LYEL News From Around the Web

Below are the latest news stories about Lyell Immunopharma Inc that investors may wish to consider to help them evaluate LYEL as an investment opportunity.

Biotech IPOs Have Slowed to a Snail's Pace

Decline tied to falling stock prices of newly minted companies

Yahoo | February 17, 2022

Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the appointment of Gary Lee, Ph.D., as Chief Scientific Officer. A veteran biotech leader with more than a decade of experience heading translational cell and gene therapy programs, Dr. Lee will set and oversee the company’s research strategy and advance its research pipeline

Yahoo | January 31, 2022

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL ), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL132, an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1) that the company is developing in collaboration with GSK. LYL132 incorporates Epi-R, Lyell''s epigenetic reprogramming technology and is under investigation as a potential next-generation enhancement to letetresgene autoleucel (lete-cel), a GSK TCR therapy targeting N...

Benzinga | January 24, 2022

FDA Clears Lyell Immunopharma' LYL132 Trial For Solid Tumors

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in solid tumors. LYL132 is an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1). LYL132 incorporates Epi-R, Lyell's epigenetic reprogramming technology, and is under investigation as a potential next-generation enhancement to letetresgene autoleucel (lete-cel), a

Yahoo | January 24, 2022

Superstar biotech execs, scientists, funders launch $3 billion company to 'reverse disease'

Backed by $3 billion and some of biotech's biggest names, Altos Labs officially emerged from stealth with the ambitious task of reversing disease. The company, which the San Francisco Business Times previously reported had leased space in Redwood City, will be led by former Genentech Inc. chief medical officer Hal Barron, who currently is president of research and development at GlaxoSmithKline plc and held the same position at aging disease research pioneer Calico. Rick Klausner, the former National Cancer Institute chief and founder of a handful of biotech companies, including South San Francisco's Lyell Immunopharma Inc. (NASDAQ: LYEL), is chief scientist, and Grail Inc. founder and former president Hans Bishop will be president.

Yahoo | January 19, 2022

Read More 'LYEL' Stories Here

LYEL Price Returns

1-mo -15.40%
3-mo -37.28%
6-mo -53.08%
1-year N/A
3-year N/A
5-year N/A
YTD -43.93%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6806 seconds.